AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is conducting a Phase 1 clinical study titled ‘A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)’. The study aims to evaluate the safety and tolerability of AZD9833, both as a standalone treatment and in combination with other drugs, for women with advanced breast cancer that is resistant to endocrine therapy.
The study is testing AZD9833, a drug intended to treat endocrine-resistant ER+ HER2- breast cancer. It is being evaluated alone and in combination with other drugs like palbociclib, everolimus, abemaciclib, capivasertib, ribociclib, and anastrozole, to determine the most effective and safe dosage.
This interventional study is randomized and follows a sequential intervention model, focusing on treatment. There is no masking involved, meaning all participants and researchers know which treatments are being administered.
The study began on October 11, 2018, with its primary completion and estimated completion dates not specified. The last update was submitted on July 8, 2025, indicating ongoing progress in the study.
This update could influence AstraZeneca’s stock performance positively if the results show promise, as it would strengthen their oncology portfolio. Competitors in the oncology space may also feel pressure to advance their own research initiatives.
The study is ongoing, with further details available on the ClinicalTrials portal.